CoChat

The use of clinical study reports to enhance the quality of systematic reviews: a survey of systematic review authors

Open access

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Clinical study reports (CSRs) are produced for marketing authorisation applications. They often contain considerably more information about, and data from, clinical trials than corresponding journal publications. Use of data from CSRs might help circumvent reporting bias, but many researchers appear to be unaware of their existence or potential value. Our survey aimed to gain insight into the level of familiarity, understanding and use of CSRs, and to raise awareness of their potential within the systematic review community. We also aimed to explore the potential barriers faced when obtaining and using CSRs in systematic reviews. METHODS: Online survey of systematic reviewers who (i) had requested or used CSRs, (ii) had considered but not used CSRs and (iii) had not considered using CSRs was conducted. Cochrane reviewers were contacted twice via the Cochrane monthly digest. Non-Cochrane reviewers were reached via journal and other website postings. RESULTS: One hundred sixty respondents answered an open invitation and completed the questionnaire; 20/160 (13%) had previously requested or used CSRs and other regulatory documents, 7/160 (4%) had considered but not used CSRs and 133/160 (83%) had never considered this data source. Survey respondents mainly sought data from the European Medicines Agency (EMA) and/or the Food and Drug Administration (FDA). Motivation for using CSRs stemmed mainly from concerns about reporting bias 11/20 (55%), specifically outcome reporting bias 11/20 (55%) and publication bias 5/20 (25%). The barriers to using CSRs noted by all types of respondents included current limited access to these documents (43 respondents), the time and resources needed to obtain and include these data in evidence syntheses (n = 25) and lack of guidance about how to use these sources in systematic reviews (n = 26). CONCLUSIONS: Most respondents (irrespective of whether they had previously used them) agreed that access to CSRs is important, and suggest that further guidance on how to use and include these data would help to promote their use in future systematic reviews. Most respondents who received CSRs considered them to be valuable in their systematic review and/or meta-analysis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13643-018-0766-x

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Flow diagram of combined survey responses with responses in each domain of interest
Fig. 1 Flow diagram of combined survey responses with responses in each domain of interestCC BY · PubMed Central
Fig. 2 Sources of data for the respondents who requested regulatory/non-regulatory data and the success rate obtaining the data. *Larger companies include GSK (n = 1 request (1: successful request)), Pfizer (n = 2 (2)), Eli Lilly (n = 1 (1)), Bristol-Myers Squibb (n = 2 (1)), Merck (n = 1 (0)), Genentech (n = 1 (1)). **Smaller companies include (2) Helsinn, (2) Schering-Plough, (1) Salix Pharmaceuticals, (1) PharmaSwiss, (1) Cubist Pharmaceuticals, (1) Pharmaxis, (1) Santhera. **(1) Request was made to the US’s National Institute for Occupational Safety and Health (NIOSH) and the other to Health Canada
Fig. 2 Sources of data for the respondents who requested regulatory/non-regulatory data and the success rate obtaining the data. *Larger companies include GSK (n = 1 request (1: successful request)), Pfizer (n = 2 (2)), Eli Lilly (n = 1 (1)), Bristol-Myers Squibb (n = 2 (1)), Merck (n = 1 (0)), Genentech (n = 1 (1)). **Smaller companies include (2) Helsinn, (2) Schering-Plough, (1) Salix Pharmaceuticals, (1) PharmaSwiss, (1) Cubist Pharmaceuticals, (1) Pharmaxis, (1) Santhera. **(1) Request was made to the US’s National Institute for Occupational Safety and Health (NIOSH) and the other to Health CanadaCC BY · PubMed Central
Fig. 3 Criteria considered most important when considering using regulatory data (n = 14)
Fig. 3 Criteria considered most important when considering using regulatory data (n = 14)CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Research works printed but not linked: 1

  1. Lefebvre C, Manheimer E, Glanville J. Chapter 6: searching for studies. In: JPT H, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated March 2011): The Cochrane Collaboration; 2011. http://training.cochrane.org/handbook .

Cited by

See all 50

Metadata

Authors
Hodkinson, A., Dietz, K. C., Lefebvre, C., Golder, S., Jones, M., Doshi, P., Heneghan, C., Jefferson, T., Boutron, I., & Stewart, L.
Affiliations
  • University of York (GB)
  • The University of Queensland (AU)
  • University of Maryland, Baltimore (US)
  • University of Oxford (GB)
  • Inserm (FR)
Venue
Systematic Reviews
Published
2018-08-08
Volume
7
Issue
1
Pages
117-117
ISSN
2046-4053 (ISSN-L)
OpenAlex
W2885475459
Cited by
49
References
24
Citations by year
2025: 6 · 2024: 3 · 2023: 4 · 2022: 1 · 2021: 26 · 2020: 4 · 2019: 4 · 2018: 1
FWCI
1.72
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • creativecommons.org/licenses/by/4.0/ (tdm)
Locations
  • Systematic Reviews (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Kent Academic Repository (University of Kent) (acceptedVersion)
  • White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Research Explorer (The University of Manchester) (submittedVersion, other-oa)
Funders
Cochrane methods innovation fund (N/A)
Topics
  • Social Sciences › Decision Sciences › Statistics, Probability and Uncertainty › Meta-analysis and systematic reviews
  • Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
  • Social Sciences › Library and Information Sciences › Academic Publishing and Open Access
Keywords
clinical study reports, reporting bias, selective reporting, publication bias, regulatory documents, barriers to data use, European Medicines Agency, Food and Drug Administration
MeSH terms
Systematic Reviews as Topic, Authorship, Humans, Surveys and Questionnaires, Publication Bias, Research Report

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The use of clinical study reports to enhance the quality of systematic reviews: a survey of systematic review authors. https://app.cochat.ai/papers/10.1186/s13643-018-0766-x
The paper
Hodkinson, A., Dietz, K. C., Lefebvre, C., Golder, S., Jones, M., Doshi, P., Heneghan, C., Jefferson, T., Boutron, I., & Stewart, L. (2018). The use of clinical study reports to enhance the quality of systematic reviews: a survey of systematic review authors. Systematic Reviews. https://doi.org/10.1186/s13643-018-0766-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.